Navigation Links
Mundipharma's Commitment to Accelerated Business Growth Supported by Appointment of Paul Medeiros to Head Its Corporate and Business Development
Date:3/14/2012

CAMBRIDGE, England, March 14, 2012 /PRNewswire/ -- Mundipharma International has appointed Paul Medeiros to head its corporate and business development operations. In this position, Mr. Medeiros will join the Executive Leadership Team and play a critical role in extending and expanding avenues for corporate growth within Mundipharma's European independent associated companies, many of which are growing faster than any other midsized pharmaceutical companies in the market.

Mr. Medeiros brings over 19 years of experience in biopharmaceutical business development and commercialization and a significant track record of success in technology acquisitions, in- and out-licensing, and strategic alliance development across a therapeutic areas. He most recently served as Senior Vice President and Chief Business Officer at AVI BioPharma, a technology-innovating developer of RNA-based therapeutics for rare diseases. In that role, he was responsible for all business development and licensing activity, establishment of academic and commercial research collaborations, product portfolio planning and corporate strategy development. At AVI, he was instrumental in obtaining over $300 million in non-dilutive collaboration funding for the company. Previously, Mr. Medeiros served as Vice President, Global Licensing and Strategic Alliances for Schering-Plough, where he led worldwide product licensing and strategic partnering initiatives in specialist product categories. Mr. Medeiros began his biopharmaceutical career at Merck & Company, where he held positions in field sales, new product planning and worldwide marketing.

"Paul's deep experience and network in the pharma industry, combined with his entrepreneurial mind-set and nuanced understanding of the business, will be essential for Mundipharma's continued growth," said Antony Mattessich, Regional Director, Mundipharma Europe. "We are thrilled to add his energy and expertise to our team, and we look forward to working with him to build stronger partnerships worldwide."

"Mundipharma's culture and approach to business are unique in the pharmaceutical industry. I am genuinely excited to be joining such an ambitious, growing organisation," said Mr. Medeiros.

Paul Medeiros holds an A.B. with honours from Brown University and an M.B.A. from Columbia Business School. He is a member of the Licensing Executives Society and is a Certified Licensing Professional™.

About Mundipharma International Limited

The Mundipharma/Napp/Norpharma independent associated companies are privately owned companies and joint ventures covering the world's pharmaceutical markets. The companies worldwide are dedicated to bringing to patients with severe and debilitating diseases the benefits of novel treatment options in fields such as severe pain, haemato-oncology and respiratory disease. For more information: www.mundipharma.co.uk


'/>"/>
SOURCE Mundipharma International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma® Life Science Obtains Global License for Kyoto Universitys iPS Cell Patent Portfolio, Deepens Commitment to Drug Discovery and ADME/Toxicology
2. Aptuit Completes Sale of CTS to Catalent; Reinforces Commitment to Scientific Excellence and Most Comprehensive Early to Mid-Phase Development Capability
3. PA Governor Corbett Visits Future Site of Endo Pharmaceuticals HQ; Praises Company for its Continued Commitment to Pennsylvania
4. Chile, U.S. Strengthen Ties, Commitment to Quality Medicines
5. Pioneering Gift From the Sumner M. Redstone Foundation Leads to $118 Million Multi-Country Commitment to End Polio
6. Philips Enters North American Mammography Market, Underscoring its Global Commitment to Womens Health Care
7. UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting
8. Philips Teams up With Integrated Oncology Network, Reinforcing Its Commitment to the Future of Cancer Care
9. Medical Alarm Concepts Receives Growth Capital Injection and Commitment for Future Funding
10. Commonwealth Welcomes Global Commitment to Combat Non-Communicable Diseases
11. BD to Increase Access to Vital Cervical Cancer Screening in Resource-Limited Settings Through Commitment to Pink Ribbon Red Ribbon Initiative®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch die CFDA sowie ... – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the Chinese Congress ... Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016  Boehringer Ingelheim announced today ... Equality Index (CEI). This is the ninth time that ... designated as a Best Place to Work for LGBT ... CEI is a national benchmarking report on corporate policies ... bisexual and transgender (LGBT) employees. "We ...
Breaking Medicine Technology:
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 , ... ... decreases in medical payments per workers’ compensation claim in 2013 and 2014, according to ... Workers Compensation Research Institute (WCRI) . , According to the study, medical payments per ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance Agency, ... Hamilton County, is embarking on a charity drive with the aim of generating ... for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally owned ... clients in the northern Alabama and Georgia regions, is embarking on a charity ... Works has built a network of support and education facilities to develop and ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
(Date:12/7/2016)... Atlanta, Georgia (PRWEB) , ... ... ... announced today it has acquired Presence Technology, S.L. (“Presence”) for a purchase ... certain price adjustments and other considerations. Presence’s annual revenue is approximately $13.2 ...
Breaking Medicine News(10 mins):